CTLA4 and experimental autoimmune encephalomyelitis: For example, blocking CTLA-4 in a relapsing–remitting experimental autoimmune encephalomyelitis mice model has been shown to exacerbate clinical disease and inhibit clinical remission through enhanced T cell reactivity to epitopes associated with induction and relapse (61).